Sucampo shutters development effort after lead drug flops in back-to-back studies
Back in April, when Sucampo’s lead experimental drug cobiprostone flunked its first mid-stage study, the Rockville, MD-based biotech stubbornly insisted that an ongoing study for another indication offered a whole new pathway forward. Today, that road came to an end, and the drug did too.
A futility analysis of the drug in a Phase IIa study of an oral spray formulation of cobiprostone for the prevention of oral mucositis in patients that are undergoing radio chemotherapy for head and neck cancer concluded that the study was another flop. And Sucampo says it’s moving on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.